AGEN earnings date and last-quarter result: next report 2026-08-10, last quarter miss, P/E 3.20. Updated 2026-07-23.
Agenus (AGEN) Research Hub
Agenus (AGEN) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-10-26, shares last closed at 6.16 USD (-2.69%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E 3.20, market cap 0.24B. This hub links to the full technical, earnings and options research available for AGEN.
Last updated 2026-10-26 · Source: end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 6.16 USD (-2.69%) |
| 52-week range | 2.86 USD – 10.31 USD |
| Trend regime | Range |
| 14-day RSI | 28.5 (Oversold) |
| Trailing P/E | 3.20 |
| Market cap | 0.24B |
| Dividend yield | 0.00% |
| Next earnings | 2026-08-10 |
Available research for AGEN
Covered Call on AGEN: how it works, illustrative setup around the real 6.16 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on AGEN: how it works, illustrative setup around the real 6.16 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on AGEN: how it works, illustrative setup around the real 6.16 USD price, max profit/loss, breakeven and when to use it. Educational.
AGEN technical analysis: range, last 6.16 USD, RSI 28.5, 52w range 2.86 USD–10.31 USD, real support/resistance. Updated 2026-10-26.
More on SniperIQ
Frequently asked questions
What sector is AGEN in?
Agenus (AGEN) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is AGEN in an uptrend or downtrend?
As of 2026-10-26, AGEN is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is AGEN's trailing P/E ratio?
AGEN's trailing P/E is 3.20, with a market cap of 0.24B. See the earnings research page for full valuation detail.
When does AGEN next report earnings?
AGEN is next scheduled to report earnings on 2026-08-10.